KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Goodwill & Intangibles: 2019-2025

Historic Goodwill & Intangibles for Royalty Pharma (RPRX) over the last 2 years, with Sep 2025 value amounting to $924.6 million.

  • Royalty Pharma's Goodwill & Intangibles was N/A to $924.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $924.6 million, marking a year-over-year change of. This contributed to the annual value of $5.7 million for FY2021, which is 80.22% down from last year.
  • Latest data reveals that Royalty Pharma reported Goodwill & Intangibles of $924.6 million as of Q3 2025, which was down 0.00% from $924.6 million recorded in Q2 2025.
  • Royalty Pharma's Goodwill & Intangibles' 5-year high stood at $924.6 million during Q2 2025, with a 5-year trough of $5.7 million in Q4 2021.
  • For the 1-year period, Royalty Pharma's Goodwill & Intangibles averaged around $924.6 million, with its median value being $924.6 million (2025).
  • Data for Royalty Pharma's Goodwill & Intangibles shows a maximum YoY slumped of 80.22% (in 2021) over the last 5 years.
  • Quarterly analysis of 2 years shows Royalty Pharma's Goodwill & Intangibles stood at $5.7 million in 2021, then followed by $924.6 million in 2025.
  • Its last three reported values are $924.6 million in Q3 2025, $924.6 million for Q2 2025, and $5.7 million during Q4 2021.